Xphozah (tenapanor)

Self-Administration – Oral Tablets

Diagnosis considered for coverage:
  • Hyperphosphatemia in Chronic Kidney Disease on Dialysis: Indicated to reduce serum phosphorus (sPh) in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Coverage Criteria:

For diagnosis of Hyperphosphatemia in Chronic Kidney Disease on Dialysis:

  • Diagnosis of hyperphosphatemia in chronic kidney disease AND
  • Patient is on dialysis AND
  • Trail (minimum 30- day supply) and inadequate response, contraindication or intolerance to two of the following: 
    • calcium carbonate 
    • calcium acetate 
    • lanthanum carbonate 
    • sevelamer carbonate 
    • sevelamer HCl 
    • Velphoro 
Dosing: 

For diagnosis of Hyperphosphatemia in Chronic Kidney Disease on Dialysis:

  • Recommended initial dose: 30 mg by mouth twice daily prior to morning and evening meals
  • Dose can be adjusted down in 10 mg increments depending on sPh and GI tolerability
  • Patient should be instructed to hold the morning dose on dialysis days, taking their dose right before the next meal following dialysis
  • Missed dose: Skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the same time
Coverage Duration: 
  • Initial: 12 months
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Administer immediately prior to breakfast or first meal of the day and immediately prior to dinner
  • Do not administer dose right before a hemodialysis session, instead take right before the next meal following dialysis, as patients may experience diarrhea after taking dose
  • Discontinue treatment in patient who develop severe diarrhea
  • Xphozah (tenapanor) is the first Food and Drug Administration (FDA)-approved phosphate-lowering agent that targets the passive uptake of phosphate from the GI tract.
  • Tenapanor may be considered as monotherapy in patients with a demonstrated intolerance or contraindication to PBs but should not be used preferentially over these agents due to a lower magnitude of phosphate-lowering effect. 
  • Xphozah (tenapanor) is contraindicated in pediatric patients < 6 years of age and in patients with known or suspected mechanical GI obstruction. 
Policy Updates:
  • 6/1/2024 (policy effective date)- New Xphozah Criteria (P&T 5/20/2024) (P&T Meeting May)
References:
  1. Xphozah [prescribing information]. Waltham, MA. Ardelyx Inc. October 2023. 
  2. UptoDate. Management of hyperphosphatemia in adults with chronic kidney disease. Available at: https://www.uptodate.com/contents/management-of-hyperphosphatemia-in-adults-with-chronic-kidney-disease?search=dialysis%20in%20chronic%20kidney%20disease&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4#H169682201. Accessed December 11, 2023. 
  3. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340919/. Accessed December 11, 2023. 
  4. Tenapanor. IBM Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Accessed March 11, 2024. http://www.micromedexsolutions.com. 

Last review date: June 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone